Detalles de la búsqueda
1.
Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
BJU Int
; 120(4): 562-575, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28418102
2.
Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).
Int J Clin Pract
; 71(5)2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28419650
3.
Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year.
Int J Urol
; 21(10): 960-7, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25092441
4.
Urodynamics and safety of the ß3-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction.
J Urol
; 190(4): 1320-7, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23727415
5.
Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
Eur Urol
; 70(1): 136-145, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26965560
6.
Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a ß(3)-adrenoceptor agonist, in overactive bladder.
Eur Urol
; 63(2): 296-305, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23195283
Resultados
1 -
6
de 6
1
Próxima >
>>